Wall Street analysts predict that iTeos Therapeutics, Inc. (NASDAQ:ITOS) will report $329.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for iTeos Therapeutics’ earnings, with estimates ranging from $19.50 million to $640.00 million. The company is expected to announce its next earnings report on Thursday, November 11th.
On average, analysts expect that iTeos Therapeutics will report full-year sales of $439.67 million for the current year, with estimates ranging from $39.00 million to $655.00 million. For the next financial year, analysts forecast that the company will post sales of $69.06 million, with estimates ranging from $60.00 million to $78.13 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for iTeos Therapeutics.
iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.34).
In related news, CEO Michel Detheux sold 8,248 shares of iTeos Therapeutics stock in a transaction dated Friday, August 27th. The shares were sold at an average price of $28.17, for a total transaction of $232,346.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 14,294 shares of the business’s stock in a transaction dated Wednesday, September 22nd. The shares were sold at an average price of $27.54, for a total transaction of $393,656.76. The disclosure for this sale can be found here. In the last three months, insiders sold 260,822 shares of company stock valued at $7,405,358. Insiders own 3.95% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in iTeos Therapeutics during the 2nd quarter worth approximately $3,666,000. Marshall Wace North America L.P. bought a new stake in iTeos Therapeutics during the 2nd quarter worth approximately $5,416,000. Morgan Stanley boosted its stake in shares of iTeos Therapeutics by 62,469.9% in the 2nd quarter. Morgan Stanley now owns 91,352 shares of the company’s stock valued at $2,344,000 after purchasing an additional 91,206 shares during the last quarter. Metropolitan Life Insurance Co NY boosted its stake in shares of iTeos Therapeutics by 110,800.0% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 6,654 shares of the company’s stock valued at $171,000 after purchasing an additional 6,648 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at $234,000. Institutional investors and hedge funds own 83.69% of the company’s stock.
ITOS traded down $0.21 during mid-day trading on Friday, hitting $27.25. The stock had a trading volume of 2,121 shares, compared to its average volume of 326,354. The stock’s fifty day simple moving average is $26.41 and its 200-day simple moving average is $26.12. The firm has a market capitalization of $959.47 million, a price-to-earnings ratio of -13.40 and a beta of 2.43. iTeos Therapeutics has a 1-year low of $17.43 and a 1-year high of $47.61.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Article: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.